In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Morrone, Fernanda B ^a,c   Oliveira, Diogo L ^a   Gamermann, Patrícia ^a   Stella, Joseli ^a   Wofchuk, Suzana ^a   Wink, Márcia R ^a   Meurer, Luise ^b   Edelweiss, Maria Isabel A ^b   Lenz, Guido ^a   Battastini, Ana Maria O ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; APYRASE; CD31 ANTIGEN; COMPLEMENTARY DNA; EOSIN; HEMATOXYLIN; KI 67 ANTIGEN; RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CANCER CELL CULTURE; CANCER GROWTH; CELL NUCLEUS; CONTROLLED STUDY; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MITOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; RAT; REAL TIME POLYMERASE CHAIN REACTION; STRIATE CORTEX; TUMOR VOLUME;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; APYRASE; BRAIN NEOPLASMS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; MALE; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33749602019     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-226     Document Type: Article

References (36)

1. Laws ER, Shaffrey ME Jr: The inherent invasiveness of cerebral gliomas: implications for clinical management. Int J Neurosci 1999, 17:413-420.
2. Holland EC: Gliomagenesis: genetic alterations and mouse models. Nature 2001, 2:120-129.
3. Grobben B, De Deyn PP, Slegers H: Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res 2002, 310(3):257-70.
4. Kaczarek E, Zapf S, Bouterfa H, Tonn JRC, Westphal M, Giese A: Dissecting glioma invasion: interrelation of adhesion, migration and intercellular contacts determine the invasive phenotype. Int J Devl Neur 1999, 17:625-641.
5. Chintala SK, Tonn JC, Rao JS: Matrix metalloproteinases and their biological function in human gliomas. Int J Devl Neur 1999, 17:495-502.
6. Plate KH, Millauer B, Ullrich A, Risau W: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993, 53:5822-5827.
7. Schaper W, Buschmann I: VEGF and therapeutic opportunities in cardiovascular diseases. Cur Op Biotec 1999, 10:541-543.
8. Ye ZC, Sontheimer H: Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999, 59:4383-4391.
9. Takano T, Lin JHC, Arcuino G, Gao Q, Yang J, Nedergaard M: Glutamate release promotes growth of malignant gliomas. Nature Med 2001, 7:1010- 1015.
10. Eyupoglu IY, Hahnen E, Heckel A, Siebzehnrubl FA, Buslei R, Fahlbusch R, Blumcke I: Malignant glioma-induced neuronal cell death in an organotypic glioma invasion model. J Neurosurg 2005, 102(4):738-44.
11. Ralevic V, Burnstock G: Receptors for purines and pyrimidines. Pharmacol Rev 1998, 50:413-492.
12. White N, Burnstock G: P2 receptors and cancer. Trends Pharmacol Sci 2006, 27(4):211-217.
13. Sabala P, Czajkowski R, Przybylek K, Kalita K, Kaczmarek L, Baranska J: Two subtypes of G protein-coupled nucleotide receptors, P2Y(1) and P2Y(2) are involved in calcium signalling in glioma C6 cells. Br J Pharmacol 2001, 132(2):393-402.
14. Czajkowski R, Baranska J: Cross talk between the ATP and ADP nucleotide receptor signalling pathways in glioma C6 cells. Acta Biochim Pol 2002, 49:877-889.
15. Czajkowski R, Banachewicz W, Ilnytska O, Drobot LB, Baranska J: Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signalling and cell proliferation in serum-deprived and nonstarved glioma C6 cells. Br J Pharmacol 2004, 141:497-507.
16. Baranska J, Czajkowski R, Sabala P: Cross-talks between nucleotide receptor-induced signalling pathways in serum-deprived and non-starved glioma C6 cells. Adv Enzyme Regul 2004, 44:219-232.
17. Morrone FB, Jacques-Silva MC, Horn AP, Bernardi A, Schwartsmann G, Rodnight R, Lenz G: Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines. J Neuroncol 2003, 64:211-218.
18. Morrone FB, Horn AP, Stella J, Spiller F, Salbego C, Lenz G, Battastini AMO: Increased resistance of glioma cell lines to extracellular ATP cytotoxicity. J Neuroncol 2005, 71:135-140.
19. Wink MR, Lenz G, Braganhol E, Tamajusuku AS, Schwartsmann G, Sarkis JJ, Battastini AMO: Altered extracellular ATP, ADP and AMP catabolism in glioma cell lines. Cancer Lett 2003, 198:211-218.
20. Neary JT, Kang Y, Tran M, Feld J: Traumatic injury activates protein kinase B/Akt in cultured astrocytes: role of extracellular ATP and P2 purinergic receptors. J Neurotrauma 2005, 22(4):491-500.
21. Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP, Dolan ME, Bigner DD, Friedman HS: Schedule-dependent activity of temozolomide plus CPT-II against a human central nervous system tumor-derived xenograft. Clin Cancer Res 2000, 6:4154-4157.
22. 2+-ATPase activity. Anal Biochem 1986, 157:375-80.
23. Zerbini LF, Wang Y, Cho JY, Libermann TA: Constitutive activation of nuclear factor kB p50/p65 and Fra-I and junD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003, 63:2206-2215.
24. Vollmayer P, Koch M, Braun N, Heine P, Servos J, Israr E, Kegel B, Zimmermann H: Multiple ecto-nucleotidases in PC12 cells: identification and cellular distribution after heterologous expression. J Neurochem 2001, 78(5):1019-1028.
25. Newlands ES, Foster T, Zaknoen S: Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer 2003, 89(2):248-251.
26. Zimmermann H: Ectonucleotidases: Some recent developments and note on nomenclature. Drug Dev Res 2001, 52:44-56.
27. Shi JD, Kukar T, Wang CY, Li QZ, Cruz PE, Davoodi-Semiromi A, Yang P, Gu Y, Lian W, Wu DH, She JX: Molecular cloning and characterization of a novel mammalian endo-apyrase (LALP1). J Biol Chem 2001, 276:7474-17478.
28. Bigonnesse F, Lévesque AS, Kukulski F, Lecka J, Robson SC, Fernandes MJG, Sévigny J: Cloning and Characterization of Mouse Nucleoside Triphosphate Diphosphohydrolase-8. Biochemistry 2004, 43:5511-5519.
29. Dzhandzugazyan KN, Kirkin AF, thor Straten P, Zeuthen J: Ecto-ATP diphsophohydrolase/CD39 is over expressed in differentiated human melanomas. FEBS Let 1998, 430:227-230.
30. Knowles FA: Inhibition of growth and induction of enzyme activities in a clonal human hepatoma cell line (Li7A): comparison on the effects of epidermal growth factor and an anti-epidermal growth factor receptor antibody. J Cell Physiol 1988, 134:109-116.
31. 2+-AtPase activities in human hepatoma cells. Arch Biochem Biophys 1988, 263:264-271.
32. Paez JG, Recio JA, Rouzaut A, Notario V: Identity between the PCPH proto-oncogene and the CD39L4 (ENTPD5) ectonucleoside triphosphate diphosphohydrolase gene. Int J Onco 2001, 19:1249-1254.
33. Amadio S, D'Ambrosi N, Cavaliere F, Murra B, Sancesario G, Bernardi G, Burnstock G, Volonté C: P2 receptor modulation and cytotoxic function in cultured CNS neurons. Neuropharmacol 2002, 42:489-501.
34. Heine P, Braun N, Heilbronn A, Zimmermann H: Functional characterization of rat ecto-ATPase and ecto-ATP diphosphohydrolase after heterologous expression in CHO cells. Eur J Biochem 1999, 262(1):102-107.
35. Auguste P, Gürsel DB, Lemière S, Reimers D, Cuevas P, Carceller F, Di Santo JP, Bikfalvi A: Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and-independent mechanisms. Cancer Res 2001, 61:1717-1726.
36. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Borea PA: Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-I in human glioblastoma cells. Biochem Pharmacol 2006, 72(1):19-31.